A ortic stenosis (AS) has been conceptualized as a mechanical problem (valve obstruction) requiring a mechanical solution (valve replacement).
Blood Pressure and Arterial Load After TAVR
several observations now suggest that treating and controlling hypertension in patients with AS should be recommended. 6 First, the prevalence of hypertension is ≥75% in recent series of older patients with AS. 7, 8 Second, there is a growing recognition that higher blood pressure and increased arterial load increase LV afterload in patients with AS, which has adverse consequences on LV remodeling and function and survival. [9] [10] [11] [12] [13] Finally, accumulating evidence, including the compelling results of SPRINT (Systolic Blood Pressure Intervention Trial), emphasizes the benefit of lower systolic blood pressure (SBP) targets for clinical outcomes, even among adults >75 years of age. [14] [15] [16] After aortic valve replacement, residual LV afterload often is estimated by assessing the transvalvular pressure gradient, effective orifice area, and degree of valve prosthesis-patient mismatch. 17, 18 However, focusing on valve hemodynamics alone may be inadequate as evidenced by a recent study showing increased vascular stiffness after transcatheter aortic valve replacement (TAVR). 19 Total vascular hydraulic load includes steady and pulsatile components. Steady load is represented by systemic vascular resistance, whereas pulsatile load is because of wave reflections and vascular stiffness. [20] [21] [22] The clinical approach of considering SBP as a surrogate for vascular load is an oversimplification, which does not consider the effects of resistive and pulsatile load separately from blood pressure. Prior small studies provided conflicting results on the association between post-TAVR blood pressure and clinical outcomes. 23, 24 Accordingly, the association of blood pressure and systemic arterial load with mortality after TAVR for severe AS is not known. 25 We hypothesized that high systemic vascular afterload-as reflected in blood pressure, pulsatile and resistive load-would be associated with adverse clinical outcomes after TAVR.
Methods

Study Population
Among patients with severe, symptomatic AS at high or prohibitive surgical risk receiving TAVR in the PARTNER I trial (Placement of Aortic Transcatheter Valve) or continued access registry, 2141 patients with an echocardiogram performed and SBP between 100 and 170 mm Hg at 30 days after TAVR were included in this analysis. Patients with SBP <100 mm Hg (n=61) or >170 mm Hg (n=54) were excluded to avoid skewing the results and making them less clinically relevant because these more extreme values were less representative of the population. The inclusion and exclusion criteria for the PARTNER I trial have previously been described. 26, 27 The first-generation Edwards SAPIEN heart valve system (Edwards Lifesciences) was used in all subjects via a transfemoral or transapical approach. The study protocol was approved by the institutional review board at each enrolling site, and all patients provided written informed consent.
Blood Pressure, Arterial Load, and Echocardiography
SBP and diastolic blood pressure (DBP) were measured, and echocardiograms obtained before TAVR and after TAVR at discharge, 30 days, 6 months, and yearly for 5 years. All echocardiograms were evaluated and measurements made by a core laboratory as described. 28 Total arterial load was measured as indexed arterial elastance ([0.9×SBP]/ stroke volume index). 29 Pulsatile arterial load was measured by pulse pressure (PP; SBP-DBP) and systemic arterial compliance (SAC), which was calculated as stroke volume index divided by PP. 
Clinical End Points
The primary end point of the PARTNER trial and our analysis was all-cause death at 1 year although we only included events between 30 days and 1 year because our variables of interest were measured at 30 days after TAVR. 26, 27 Secondary end points included cardiovascular mortality (deaths because of a cardiac or unknown cause), noncardiovascular mortality, Kansas City Cardiomyopathy Questionnaire overall summary score, LV mass index, LV ejection fraction, and 6-minute walk distance.
Statistical Analysis
Continuous variables are summarized as mean±SD or medians and quartiles and were compared using the Student t test or MannWhitney rank sum test as appropriate. Categorical variables were compared with the χ 2 or Fisher exact test. Survival curves for timeto-event variables, based on all available follow-up data, were performed with the use of Kaplan-Meier estimates and were compared between groups with the use of the log-rank test. Cox proportional hazards models were used to calculate hazard ratios and to test for interactions. Multivariable Cox models adjusted for variables forced into the models (age, effective orifice area at 30 days, TAVR approach) and additional clinical and echocardiographic variables using stepwise selection (entry/stay criteria of 0.1/0.1); candidate variables for inclusion had a univariable association with mortality (P<0.10). These models included echocardiographic variables and complications that occurred between the TAVR procedure and 30 days that were associated with mortality from 30 days to 1 year. Specifically, we adjusted for age, sex, major arrhythmia, renal disease (creatinine ≥2), liver disease, oxygen-dependent lung disease, high versus prohibitive risk patient, trial versus registry patient, transfemoral versus alternative access, aortic valve reintervention within 30 days of TAVR, major bleeding within 30 days, effective orifice area index (30 days), moderate or severe mitral regurgitation (30 days), and moderate or severe total aortic regurgitation (30 days). We split the population into 2 groups based on the median 30-day SBP. Sensitivity analyses evaluated 30-day SBP as a linear variable. Kansas City Cardiomyopathy Questionnaire overall summary scores were compared using ANCOVA to adjust for baseline differences in Kansas City Cardiomyopathy Questionnaire scores between groups. All statistical analyses were performed with SAS software, version 9.4.
Results
Patient Population
Among 2559 patients with symptomatic AS at high or prohibitive surgical risk receiving TAVR in the PARTNER I trial or continued access registry, 2141 patients were included in this analysis. Of these, 438 were enrolled in the trial (high risk, n=292; prohibitive risk, n=146) and 1703 were in the continued access registry (high risk, n=1487; prohibitive risk, n=216). Clinical and echocardiographic data, 30-day arterial load parameters, and medications are shown for the whole population and were compared between patients with a 30-day SBP 100 to 129 mm Hg versus those with 130 to 170 mm Hg (Table 1) . Further information on medication usage over time in these groups is shown in Table I in the Data Supplement. Table 2 ). Lower 30-day SBP was also associated with increased all-cause mortality when evaluated per 10-mm Hg decrease and when evaluated in groups of 10 mm Hg (100-109, 110-119, and 120-129 mm Hg) with 30-day SBP 130 to 139 mm Hg as the referent (Table 2 ). All-cause mortality for SBP groups between 140 and 170 mm Hg was similar to the referent of 130 to 139 mm Hg (Table 2) . After multivariable adjustment, all these significant associations remained so with minimal attenuation (Table 2 ). Cardiovascular mortality, but not noncardiovascular mortality, was increased in patients with 30-day SBP 100 to 129 mm Hg compared with SBP 130 to 170 mm Hg (P<0.001; Figure 1B ; Figure I in the Data Supplement). In multiple subgroups, including those based on the number of blood pressure medications prescribed, there was a consistent association between lower 30-day SBP and higher 30-day to 1-year all-cause mortality although among those with worse renal function this relationship was even stronger ( Figure 2 ). Among patients with 30-day SBP 100 to 129 mm Hg or 130 to 170 mm Hg, a decrease in SBP between 30 days and 6 months was not significantly associated with 6-month to 2-year mortality after adjustment.
Systemic Arterial Load and Mortality
Higher arterial elastance and lower SAC at 30 days after TAVR were consistently associated with increased 30-day to 1-year all-cause mortality in unadjusted and adjusted continuous and quintile-based analyses (Table 2 ). Higher PP was associated with increased mortality but only after adjustment for 30-day SBP. In contrast to measures of total and pulsatile arterial load, systemic vascular resistance at 30 days was not significantly associated with mortality in any analyses. The associations with mortality of related variables, valvuloarterial impedance and stroke volume index, at 30 days are also shown in Table 2 . each further stratified mortality based on 30-day SBP. Allcause mortality in patients with low 30-day SBP and high pulsatile load (low SAC or high PP) was over 3-fold higher than in patients with high 30-day SBP and low pulsatile load ( Figure 1C and 1D ).
Blood Pressure and Systemic Arterial Load Before and After TAVR
Pre-TAVR and post-TAVR (30 days and 6 months) measurements for blood pressure, arterial load, and other related parameters are shown in Figure 3 . The correlations between the 30-day measurements are shown in Table II 
Secondary End Points
Lower 30-day SBP was associated with a higher rate of repeat hospitalization but similar rates of stroke and renal failure requiring dialysis between 30 days and 1 year ( 
Discussion
In this study of patients treated with TAVR for severe AS, somewhat paradoxically, a lower blood pressure was associated with higher all-cause and cardiovascular mortalities. This association persisted after multivariable adjustment and was consistent across multiple subgroups, including those based on the number of blood pressure medications, and was confirmed in sensitivity analyses. In contrast, higher total and pulsatile load, as measured by elastance, SAC, and PP 30 days after TAVR, were associated with increased all-cause mortality. Although blood pressure is commonly considered to be a simple surrogate for arterial load, these data show that arterial pressure, stiffness, and resistance are not just different aspects of the same phenomenon. Rather, these are distinct physiological parameters, each of which affects clinical outcomes, at least in patients treated with TAVR for AS. Collectively, these data have important implications for blood pressure goals after TAVR in that a lower SBP is associated with adverse outcomes and suggest that targeting pulsatile arterial load may more effectively unload the heart and potentially improve outcomes after TAVR. Notably, these results are at odds with the landmark SPRINT trial, which found that compared with an SBP treatment target of <140 mm Hg, patients randomized to an SBP CI indicates confidence interval; DBP, diastolic blood pressure; Ea, arterial elastance; HR, hazard ratio; PP, pulse pressure; SAC, systemic arterial compliance; SBP, systolic blood pressure; SVi, stroke volume index; SVR, systemic vascular resistance; and ZVa, valvuloarterial impedance.
*Adjusted for age, sex, major arrhythmia, renal disease (creatinine ≥2), liver disease, oxygen-dependent lung disease, high vs prohibitive risk patient, trial vs registry patient, transfemoral vs alternative access, aortic valve reintervention within 30 days of transcatheter aortic valve replacement, major bleeding within 30 days, effective orifice area index (30 days), moderate or severe mitral regurgitation (30 days), and moderate or severe total aortic regurgitation (30 days).
†Adjusted for same variables as above+SBP (as a continuous variable). 14 Relevant to our population with a mean age of 84 years, a recent analysis of patients >75 years of age in the SPRINT trial confirmed the survival advantage associated with an SBP target <120 mm Hg. 15 We hypothesized that a higher SBP would be particularly disadvantageous to patients with AS treated with TAVR. We reasoned that after relief of pressure overload with valve replacement, regression of LV hypertrophy and improvement in LV function would be impaired by a persistently high Figure 2 . Subgroup analyses. Cox proportional hazards models were used to evaluate the hazard ratios (HRs) for 30-day to 1-year allcause death for patients with 30-day systolic blood pressure (SBP) 100 to 129 mm Hg vs 130 to 170 mm Hg in the subgroups shown. ACE-I/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BP, blood pressure; CI, confidence interval; Cr, creatinine; DBP, diastolic blood pressure; Ea, arterial elastance; EF, ejection fraction; PP, pulse pressure; SAC, systemic arterial compliance; SVR, systemic vascular resistance; and SVi, stroke volume index. Blood Pressure and Arterial Load After TAVR afterload associated with an elevated SBP, which would contribute to worse post-TAVR heart failure and survival. Instead, we found that lower, not higher, SBP was associated with worse heart failure-related quality of life and higher cardiovascular and all-cause mortality, and lower SBP was associated with worse LV function at 1 year. Similarly, lower DBP was independently associated with increased all-cause mortality. Notably, the association between lower SBP and increased mortality did not seem to be explained by procedural complications from TAVR because the incidence of these events was either similar between those with lower versus higher SBP at 30 days after TAVR or they were included in adjusted models.
There are several potential explanations for our findings. The stented profile of the valve prosthesis extends from just below the aortic annulus almost up to the sinotubular junction.
The prosthetic valve, combined with displaced calcified native leaflets, may disturb normal aortic root flow patterns and alter the blood flow from the aorta into the sinuses, potentially impairing coronary flow. Subclinical valve thrombosis also may be related to altered flow patterns or stagnation in the aortic root. 31 In addition, LV geometry in patients with AS is characterized by LV hypertrophy with more myocardium to perfuse, diastolic dysfunction, and an increased LV enddiastolic pressure, all of which reduce the coronary perfusion pressure. Thus, patients treated with TAVR for AS may require a higher blood pressure to prevent or limit subendocardial ischemia, both by overcoming impediments to flow from the aorta into the coronary arteries and by accommodating hypertrophic LV remodeling. Our data lend some support to these hypothesized mechanisms in that patients with a lower Figure 3 . Blood pressure, arterial load, valvuloarterial impedance, and flow before and after transcatheter aortic valve replacement (TAVR). Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), systemic arterial compliance (SAC), systemic vascular resistance (SVR), valvuloarterial impedance (ZVa), and stroke volume index (SVi) are shown over time before and after (30 days and 6 months) TAVR. For each measurement, data are shown for subjects with data at all available time points (baseline and post-TAVR at 30 days and 6 months). The box and whisker plots show the median values, 25th and 75th percentiles (box), and the 2.5 and 97.5 percentiles (whiskers) at baseline (gray), 30 days (blue), and 6 months (red). For each measurement, also shown are the percentages of subjects with an increase (white) vs decrease (black) in the measurement from baseline to 30 days post-TAVR; the mean and SD of that change are shown. Blood Pressure and Arterial Load After TAVR 30-day SBP had more severe angina, shorter 6-minute walk tests, worse LV function at follow-up, a worse heart failurespecific quality of life, and increased cardiovascular mortality. Finally, for reasons not yet well understood, SBP may have an inverse relationship with mortality in more frail elderly populations with multiple comorbidities. [32] [33] [34] We also found that indices of increased total (arterial elastance) and pulsatile (SAC and PP) arterial load, but not resistive load (systemic vascular resistance), were associated with increased all-cause mortality. As a measure of pulsatile load, unlike SAC, the association between higher PP and higher mortality was only observed after adjustment for SBP. Relevant to this, higher PP (bad in our analysis) tends to accompany higher SBP (good in our analysis; correlation=0.78; Table II in the Data Supplement). As such, the adverse effects of higher PP may get cancelled by the favorable effects of higher SBP. However, when one adjusts for SBP, the adverse effects of PP can be observed. In contrast, the correlation between SAC and SBP was considerably weaker (−0.43; Table II in the Data Supplement), so the adverse association between lower SAC (increased pulsatile load) and increased mortality was observed both before and after adjustment for SBP. Collectively, the change from before TAVR to 30 days and 6 months after TAVR in each of these measures of arterial load was modest or absent although others have demonstrated acute increases in arterial load immediately after TAVR. 19 Arterial load parameters further stratified outcomes beyond SBP: patients with the worst outcomes had both a lower SBP and higher pulsatile arterial load.
Pulsatile load is related to the stiffness of the conduit vessels. Stiffer vessels lead to a faster pulse wave velocity of blood ejected from the heart and faster wave reflections from vascular branch points, augmenting central aortic pressure and yielding a greater LV afterload, which then impedes LV ejection. Thus, increased pulsatile load can adversely affect LV remodeling and has been associated with increased cardiovascular event rates and all-cause mortality. [35] [36] [37] [38] Arterial stiffness, a major contributor to pulsatile load, is the result of a complex interplay of endothelial and smooth muscle cell function, extracellular matrix composition, genetics, hemodynamic factors, vasoactive properties, aging and metabolic abnormalities, and systemic inflammation. 39 Strategies to reduce aortic stiffness include lifestyle modifications, such as exercise, weight loss, reduced salt intake, and moderate alcohol use, as well as pharmacological approaches. 39 Most current pharmacological approaches target vasoconstriction and affect blood pressure; in contrast, therapy that directly targets the vascular structure includes inhibiting formation of advanced glycation end products or cleaving existing cross-links. 40 Although these findings have important clinical implications, particularly in light of the recent emphasis on the benefits of lower blood pressure, further studies are needed to replicate these data and to identify optimal blood pressure targets for patients with AS treated with TAVR. This was not a randomized strategy trial of lower versus higher SBP targets but was a retrospective analysis based on a 1-time blood pressure measurement obtained in the clinic setting. Despite extensive adjustment, lower SBP may be a marker for an unmeasured confounder and not causally related to adverse outcomes. Our data did not include measures of frailty, which may affect this relationship. Whether surgical versus transcatheter valve replacement affects blood pressure targets should be examined. Arterial load was neither measured invasively nor directly by impedance or pulse wave velocity but relied on noninvasive measurements. Nonetheless, these noninvasive measurements correlate well with invasive measurements and are more feasible to obtain in large numbers of patients. 29, 30, 41 Stroke volume, used in many of the calculations for arterial load parameters, was only determined by the Doppler method. Because both lower SBP and DBP were associated with worse outcomes, the relative importance of and interplay between SBP and DBP with respect to clinical outcomes needs to be clarified. Longer term clinical outcomes will also be important to evaluate in future studies.
In conclusion, these findings draw attention to the important contribution of blood pressure and arterial load to clinical outcomes in patients with a history of AS. Importantly, although lower SBP targets may be desirable in the general population, optimal targets may differ in patients treated for AS with TAVR. However, these findings require confirmation in other cohorts, and further studies are needed to phenotype the vasculature in patients with AS, elucidate its contribution to LV afterload and clinical outcomes, and test whether adjunctive therapies targeting pulsatile load may improve survival and quality of life in patients treated with TAVR.
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